Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice

被引:26
作者
Zhou, Mingkui [1 ]
Kostoula, Ioanna [2 ]
Brill, Boris [1 ]
Panou, Eugenia [2 ]
Sakarellos-Daitsiotis, Maria [2 ]
Dietrich, Ursula [1 ]
机构
[1] Inst Biomed Res, D-60596 Frankfurt, Germany
[2] Univ Ioannina, Dept Chem, Sect Organ Chem & Biochem, GR-45110 Ioannina, Greece
关键词
HIV-1; Gp41; Epitopes; Sequential oligopeptide carriers; Immunogens; Neutralizing antibodies; IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODIES; 2F5; CARRIERS; BROAD; SPECIFICITIES; GLYCOPROTEIN; PROTECTION; CHALLENGE; PEPTIDES;
D O I
10.1016/j.vaccine.2012.01.026
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Peptide mimics of epitopes for pathogen-specific antibodies present in patient sera can be selected based on the phage display technology. Such mimotopes potentially represent vaccine candidates in case they are able to induce neutralizing antibodies upon vaccination. Here we analyze the immunogenicity of different conjugates of epitope EC26-2A4 localizing to the membrane proximal external region (MPER) of the HIV-1 transmembrane protein gp41. The EC26-2A4 epitope, which overlaps with that of the broadly neutralizing monoclonal antibody (mAb) 2F5, was coupled to sequential oligopeptide carriers (SOC) or to palmitoyl acid for better immunogenicity. Upon prime-boost immunizations of mice, the peptide conjugates induced EC26-2A4 specific antibodies in all settings and mice sera neutralized HIV-1SF162.LS in standardized neutralization assays. Thus, the EC26-2A4 MPER epitope represents a promising vaccine candidate for further analysis in larger animals with respect to the breadth of the neutralizing antibodies induced. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1911 / 1916
页数:6
相关论文
共 54 条
  • [1] Synthetic carriers:: Sequential oligopeptide carriers SOCn-I and SOCn-II as an innovative and multifunctional approach
    Alexopoulos, C
    Sakarellos-Daitsiotis, M
    Sakarellos, C
    [J]. CURRENT MEDICINAL CHEMISTRY, 2005, 12 (13) : 1469 - 1479
  • [2] Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
    Baba, TW
    Liska, V
    Hofmann-Lehmann, R
    Vlasak, J
    Xu, WD
    Ayehunie, S
    Cavacini, LA
    Posner, MR
    Katinger, H
    Stiegler, G
    Bernacky, BJ
    Rizvi, TA
    Schmidt, R
    Hill, LR
    Keeling, ME
    Lu, YC
    Wright, JE
    Chou, TC
    Ruprecht, RM
    [J]. NATURE MEDICINE, 2000, 6 (02) : 200 - 206
  • [3] Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
    Binley, JA
    Wrin, T
    Korber, B
    Zwick, MB
    Wang, M
    Chappey, C
    Stiegler, G
    Kunert, R
    Zolla-Pazner, S
    Katinger, H
    Petropoulos, CJ
    Burton, DR
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (23) : 13232 - 13252
  • [4] Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C
    Binley, James M.
    Lybarger, Elizabeth A.
    Crooks, Emma T.
    Seaman, Michael S.
    Gray, Elin
    Davis, Katie L.
    Decker, Julie M.
    Wycuff, Diane
    Harris, Linda
    Hawkins, Natalie
    Wood, Blake
    Nathe, Cory
    Richman, Douglas
    Tomaras, Georgia D.
    Bibollet-Ruche, Frederic
    Robinson, James E.
    Morris, Lynn
    Shaw, George M.
    Montefiori, David C.
    Mascola, John R.
    [J]. JOURNAL OF VIROLOGY, 2008, 82 (23) : 11651 - 11668
  • [5] A Boost for HIV Vaccine Design
    Burton, Dennis R.
    Weiss, Robin A.
    [J]. SCIENCE, 2010, 329 (5993) : 770 - 773
  • [6] EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY
    BURTON, DR
    PYATI, J
    KODURI, R
    SHARP, SJ
    THORNTON, GB
    PARREN, PWHI
    SAWYER, LSW
    HENDRY, RM
    DUNLOP, N
    NARA, PL
    LAMACCHIA, M
    GARRATTY, E
    STIEHM, ER
    BRYSON, YJ
    CAO, YZ
    MOORE, JP
    HO, DD
    BARBAS, CF
    [J]. SCIENCE, 1994, 266 (5187) : 1024 - 1027
  • [7] HIV vaccine design and the neutralizing antibody problem
    Burton, DR
    Desrosiers, RC
    Doms, RW
    Koff, WC
    Kwong, PD
    Moore, JP
    Nabel, GJ
    Sodroski, J
    Wilson, IA
    Wyatt, RT
    [J]. NATURE IMMUNOLOGY, 2004, 5 (03) : 233 - 236
  • [8] Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41
    Cardoso, RMF
    Zwick, MB
    Stanfield, RL
    Kunert, R
    Binley, JM
    Katinger, H
    Burton, DR
    Wilson, IA
    [J]. IMMUNITY, 2005, 22 (02) : 163 - 173
  • [9] Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals
    Corti, Davide
    Langedijk, Johannes P. M.
    Hinz, Andreas
    Seaman, Michael S.
    Vanzetta, Fabrizia
    Fernandez-Rodriguez, Blanca M.
    Silacci, Chiara
    Pinna, Debora
    Jarrossay, David
    Balla-Jhagjhoorsingh, Sunita
    Willems, Betty
    Zekveld, Maria J.
    Dreja, Hanna
    O'Sullivan, Eithne
    Pade, Corinna
    Orkin, Chloe
    Jeffs, Simon A.
    Montefiori, David C.
    Davis, David
    Weissenhorn, Winfried
    McKnight, Aine
    Heeney, Jonathan L.
    Sallusto, Federica
    Sattentau, Quentin J.
    Weiss, Robin A.
    Lanzavecchia, Antonio
    [J]. PLOS ONE, 2010, 5 (01):
  • [10] Dissecting the neutralizing antibody-specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors
    Dhillon, Amandeep K.
    Donners, Helen
    Pantophlet, Ralph
    Johnson, Welkin E.
    Decker, Julie M.
    Shaw, George M.
    Lee, Fang-Hua
    Richman, Douglas D.
    Doms, Robert W.
    Vanham, Guido
    Burton, Dennis R.
    [J]. JOURNAL OF VIROLOGY, 2007, 81 (12) : 6548 - 6562